Evidence map›Paper›PMID 38652015›Full record

ArticleImmunity, inflammation and disease2024

Association of IL-33 in modeling type-2 airway inflammation and pulmonary emphysema in mice.

Chika Miyaoka, Masato Watanabe, Keitaro Nakamoto, Yuki Yoshida, Aya Hirata, Jumpei Aso, Hiroki Nunokawa, Manabu Ishida, Koujiro Honda, Saori Takata and 2 more

Open access · goldAbstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in Immunity, inflammation and disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Chika MiyaokaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.ORCID 0009-0004-7462-3398
Masato WatanabeDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.ORCID 0000-0001-9988-5221
Keitaro NakamotoDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Yuki YoshidaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Aya HirataDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Jumpei AsoDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Hiroki NunokawaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Manabu IshidaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Koujiro HondaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Saori TakataDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Takeshi SarayaDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Haruyuki IshiiDepartment of Respiratory Medicine, Kyorin University Faculty of Medicine, Mitaka City, Tokyo, Japan.
Kyorin University · JP

Funding

Environmental Restoration and Conservation Agency, the Grants-In-Aid for Scientific Research (KAKENHI) 15K09189Environmental Restoration and Conservation Agency, the Grants-In-Aid for Scientific Research (KAKENHI) 19KK0404Japan Society for the Promotion of Science 15K09189Japan Society for the Promotion of Science 19KK0404
6 · The paper itself

Abstract

We developed pulmonary emphysema and a type 2 airway inflammation overlap mouse model. The bronchoalveolar lavage (BAL) interleukin 13 (IL-13), IL-4, and IL-5 levels in the overlap model were higher than in the pulmonary emphysema model and lower than in the type 2 airway inflammation model, but IL-33 level in the lung was higher than in other models. IL-33 and interferon-γ (IFNγ) in lungs may control the severity of a type 2 airway inflammation in lung.

Indexed as

Disease Models, AnimalInterleukin-33Pulmonary EmphysemaAnimalsBronchoalveolar Lavage FluidInflammationInterferon-gammaLungMiceMice, Inbred C57BLIl33 protein, mouseInterferon-gammaInterleukin-33asthmaCOPDIFNγIL‐13IL‐33IL‐4IL‐5innate immunity

Identifiers

PMID38652015
PMCPMC11037248
OpenAlexW4395036962

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.